Abstract
BackgroundThe relationship between expression of FoxM1 and clinical parameters of patients with gastric cancer (GC) has yet to be fully established. MethodsA systematic search was performed. Odds ratio (OR) and confidence interval (CI) were used to assess association between expression of FoxM1 and clinical parameters and the prognostic value of patients with GC. ResultsEight studies involving 529 patients with GC were identified. Overall, the pooled results showed that expression of FoxM1 was associated with TNM stage (OR: 0.482, 95%CI: 0.275–0.845, P = 0.011), depth of invasion (OR: 0.617, 95%CI: 0.382–0.998, P = 0.049) and lymph node metastasis (OR: 2.084, 95%CI: 1.305–3.328, P = 0.002) in the patients with GC. Whereas, expression of FoxM1 was not associated with gender (OR: 1.143, 95%CI: 0.726–1.799, P = 0.564) and tumors' differentiation (OR: 0.991, 95%CI: 0.624–1.575, P = 0.971) of GC. Expression of FoxM1 was also associated with poor prognosis of overall survival (OS) in the patients with GC (one year OS: OR: 0.218, 95%CI: 0.103–0.459, P = 0.000; three years OS: OR: 0.178, 95%CI: 0.093–0.340, P = 0.000; five years OS: OR: 0.180, 95%CI: 0.095–0.341, P = 0.000). ConclusionExpression of FoxM1 is associated with TNM stage, depth of invasion, lymph node metastasis and poor prognosis of the patients with GC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
